Login to Your Account

BIA: Investment at Risk in UK’s Value-Based Pricing

By Nuala Moran
Staff Writer

Wednesday, August 28, 2013
LONDON – As the summer break comes to an end, the industry in the UK is bracing itself for the outcome of government deliberations on establishing a value-based pricing system for drugs, with the Bioindustry Association (BIA) warning that investment in biotech could be put at risk.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription